Clinical Trial

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Study acronym: LMY-920-002
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-09-15; most recent amendment 2024-10-16.
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT05546723
Lead Sponsor Luminary Therapeutics
Collaborators: The Cleveland Clinic, Case Western Reserve University
Conditions Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
Enrollment 30 participants
Start Date 2024-03-13
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-18